AstraZeneca lists €2.55 billion bond offering for trading
AstraZeneca PLC announced that its wholly owned subsidiary AstraZeneca Finance LLC has admitted debt securities totaling €2.55 billion for trading on the Main Market of the London Stock Exchange.
London – AstraZeneca PLC announced on September 1, 2026, that its wholly owned subsidiary, AstraZeneca Finance LLC, has successfully admitted debt securities valued at €2.55 billion for trading. The securities are listed on the Main Market of the London Stock Exchange.
The admission to trading follows regulatory requirements set forth by the Financial Conduct Authority's Prospectus Rules. AstraZeneca Finance LLC, identified by LEI number 549300C3HATU4Q460S18, is the issuer of these bonds. The Main Market is a regulated exchange, providing a platform for broad investor access.
While the specifics of how the raised capital will be utilized have not been detailed, bond offerings of this scale are typical for large pharmaceutical companies. Such financing typically supports ongoing research and development, capital expenditures, and general corporate activities.
This move by AstraZeneca underscores the company's active engagement with capital markets to fund its global operations. The successful listing provides liquidity and accessibility for investors interested in the company's debt instruments.